| NCT03205371 |
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers |
https://ClinicalTrials.gov/show/NCT03205371 |
Completed |
Sanofi |
2018-07-19 |
| NCT03205358 |
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT03205358 |
Completed |
Sanofi |
2015-08-19 |
| NCT03125616 |
Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B |
https://ClinicalTrials.gov/show/NCT03125616 |
Active, not recruiting |
St George’s, University of London |
2019-09-02 |
| NCT03112031 |
Treatment With Tamoxifen in Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT03112031 |
Completed |
Oxford University Clinical Research Unit, Vietnam |
2018-07-17 |
| NCT03100786 |
Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis |
https://ClinicalTrials.gov/show/NCT03100786 |
Recruiting |
Oxford University Clinical Research Unit, Vietnam |
2021-12-01 |
| NCT03092817 |
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) |
https://ClinicalTrials.gov/show/NCT03092817 |
Recruiting |
Oxford University Clinical Research Unit, Vietnam |
2021-04-01 |
| NCT03077438 |
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years |
https://ClinicalTrials.gov/show/NCT03077438 |
Completed |
Sanofi |
2017-10-10 |
| NCT02986854 |
Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination |
https://ClinicalTrials.gov/show/NCT02986854 |
Completed |
GlaxoSmithKline |
2017-07-17 |
| NCT02955862 |
Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report |
https://ClinicalTrials.gov/show/NCT02955862 |
Completed |
National Hospital for Tropical Diseases, Hanoi, Vietnam |
2017-09-30 |
| NCT02955797 |
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers |
https://ClinicalTrials.gov/show/NCT02955797 |
Completed |
Sanofi |
2017-10-26 |
| NCT02946385 |
Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents |
https://ClinicalTrials.gov/show/NCT02946385 |
Completed |
GlaxoSmithKline |
2018-02-13 |
| NCT02881957 |
Hypovitaminosis D in Neurocritical Patients |
https://ClinicalTrials.gov/show/NCT02881957 |
Completed |
University of Utah |
2018-10-10 |
| NCT02864927 |
Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea |
https://ClinicalTrials.gov/show/NCT02864927 |
Completed |
Sanofi |
2019-06-12 |
| NCT02842866 |
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older |
https://ClinicalTrials.gov/show/NCT02842866 |
Completed |
Sanofi |
2017-02-13 |
| NCT02842853 |
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT02842853 |
Completed |
Sanofi |
2017-02-28 |
| NCT02752906 |
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT02752906 |
Completed |
Sanofi |
2016-12-19 |
| NCT02724046 |
Ciprofloxacin for the Prevention of Meningococcal Meningitis |
https://ClinicalTrials.gov/show/NCT02724046 |
Completed |
Epicentre |
2017-05-30 |
| NCT02640404 |
Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam |
https://ClinicalTrials.gov/show/NCT02640404 |
Completed |
Sanofi |
2016-12-05 |
| NCT02639351 |
Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT02639351 |
Completed |
GlaxoSmithKline |
2017-08-31 |
| NCT02633787 |
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier |
https://ClinicalTrials.gov/show/NCT02633787 |
Completed |
Sanofi |
2016-02-29 |
| NCT02591290 |
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects |
https://ClinicalTrials.gov/show/NCT02591290 |
Completed |
Sanofi |
2016-03-16 |
| NCT03621670 |
GlaxoSmithKline’s (GSK) Safety and Immunogenicity Study of GSK Meningococcal Group B and 13-valent Pneumococcal Vaccines Administered Together With Routine Infant Vaccines in Healthy Infants |
https://ClinicalTrials.gov/show/NCT03621670 |
Recruiting |
GlaxoSmithKline |
2023-10-09 |
| NCT02531698 |
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years |
https://ClinicalTrials.gov/show/NCT02531698 |
Completed |
Pfizer |
2017-03-31 |
| NCT02526394 |
Pertussis and Meningitis C Concomitant Vaccination in Adolescents |
https://ClinicalTrials.gov/show/NCT02526394 |
Completed |
Public Health England |
2017-03-31 |
| NCT02451514 |
A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) |
https://ClinicalTrials.gov/show/NCT02451514 |
Completed |
GlaxoSmithKline |
2015-11-30 |
| NCT02446743 |
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents |
https://ClinicalTrials.gov/show/NCT02446743 |
Completed |
GlaxoSmithKline |
2016-09-23 |
| NCT02446691 |
Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations |
https://ClinicalTrials.gov/show/NCT02446691 |
Completed |
GlaxoSmithKline |
2017-12-28 |
| NCT02398396 |
Investigating Meningococcal Vaccines in Adults |
https://ClinicalTrials.gov/show/NCT02398396 |
Active, not recruiting |
University of Oxford |
2015-11-30 |
| NCT02285777 |
Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents |
https://ClinicalTrials.gov/show/NCT02285777 |
Completed |
GlaxoSmithKline |
2015-03-26 |
| NCT02274285 |
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants |
https://ClinicalTrials.gov/show/NCT02274285 |
Completed |
Sanofi |
2016-05-28 |
| NCT02237365 |
A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis |
https://ClinicalTrials.gov/show/NCT02237365 |
Completed |
Oxford University Clinical Research Unit, Vietnam |
2016-06-24 |
| NCT02212457 |
Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents |
https://ClinicalTrials.gov/show/NCT02212457 |
Completed |
GlaxoSmithKline |
2015-05-22 |
| NCT02199691 |
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents |
https://ClinicalTrials.gov/show/NCT02199691 |
Completed |
Sanofi |
2015-10-02 |
| NCT02173704 |
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. |
https://ClinicalTrials.gov/show/NCT02173704 |
Completed |
GlaxoSmithKline |
2015-12-25 |
| NCT02169882 |
High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study |
https://ClinicalTrials.gov/show/NCT02169882 |
Completed |
Universitas Padjadjaran |
2016-11-05 |
| NCT02141516 |
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. |
https://ClinicalTrials.gov/show/NCT02141516 |
Completed |
Novartis |
2015-03-31 |
| NCT02140762 |
Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents |
https://ClinicalTrials.gov/show/NCT02140762 |
Completed |
Novartis |
2014-11-30 |
| NCT02106390 |
Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants |
https://ClinicalTrials.gov/show/NCT02106390 |
Completed |
GlaxoSmithKline |
2016-10-14 |
| NCT01274897 |
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea |
https://ClinicalTrials.gov/show/NCT01274897 |
Completed |
Novartis |
2011-03-31 |
| NCT01272180 |
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults |
https://ClinicalTrials.gov/show/NCT01272180 |
Completed |
Novartis |
2011-10-31 |
| NCT01270503 |
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines |
https://ClinicalTrials.gov/show/NCT01270503 |
Completed |
Sanofi |
2013-12-31 |
| NCT01994629 |
Safety and Immunogenicity of One Dose of Novartis’ Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals’ Meningococcal ACWY-TT Vaccine in Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT01994629 |
Completed |
Novartis |
2014-04-30 |
| NCT01992536 |
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180) |
https://ClinicalTrials.gov/show/NCT01992536 |
Completed |
Novartis |
2014-05-31 |
| NCT01984125 |
Testing the Use of Prompts to Increase Adolescent Immunization Rates |
https://ClinicalTrials.gov/show/NCT01984125 |
Completed |
University of California, Los Angeles |
2013-01-31 |
| NCT01973218 |
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. |
https://ClinicalTrials.gov/show/NCT01973218 |
Completed |
Novartis |
2014-04-30 |
| NCT01939158 |
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer’s Prevenar 13â„¢Vaccine |
https://ClinicalTrials.gov/show/NCT01939158 |
Completed |
Pfizer |
2019-12-05 |
| NCT01934140 |
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals’ MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination |
https://ClinicalTrials.gov/show/NCT01934140 |
Completed |
Pfizer |
2018-02-28 |
| NCT01911221 |
A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. |
https://ClinicalTrials.gov/show/NCT01911221 |
Completed |
Novartis |
2014-04-30 |
| NCT01904448 |
Auditory Brainstem Implantation in Young Children |
https://ClinicalTrials.gov/show/NCT01904448 |
Completed |
University of North Carolina, Chapel Hill |
2017-10-01 |
| NCT01900899 |
Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children |
https://ClinicalTrials.gov/show/NCT01900899 |
Completed |
Pfizer |
2017-11-30 |
| NCT01897402 |
Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT01897402 |
Completed |
JN-International Medical Corporation |
2014-05-31 |
| NCT01896596 |
Hepatitis B Vaccination in Infants |
https://ClinicalTrials.gov/show/NCT01896596 |
Completed |
Public Health England |
2017-04-30 |
| NCT01890759 |
Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation |
https://ClinicalTrials.gov/show/NCT01890759 |
Completed |
Sanofi |
2016-04-12 |
| NCT01823536 |
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose |
https://ClinicalTrials.gov/show/NCT01823536 |
Completed |
Novartis |
2013-10-31 |
| NCT01802502 |
Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation |
https://ClinicalTrials.gov/show/NCT01802502 |
Completed |
Universitas Padjadjaran |
2013-10-31 |
| NCT01802385 |
Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT01802385 |
Completed |
University of Minnesota |
2017-09-30 |
| NCT01782066 |
Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines |
https://ClinicalTrials.gov/show/NCT01782066 |
Completed |
Leiden University Medical Center |
2014-02-28 |
| NCT01777308 |
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination |
https://ClinicalTrials.gov/show/NCT01777308 |
Completed |
GlaxoSmithKline |
2014-07-03 |
| NCT01767376 |
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age |
https://ClinicalTrials.gov/show/NCT01767376 |
Completed |
GlaxoSmithKline |
2014-01-16 |
| NCT01766206 |
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea |
https://ClinicalTrials.gov/show/NCT01766206 |
Completed |
GlaxoSmithKline |
2018-01-22 |
| NCT01755689 |
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults |
https://ClinicalTrials.gov/show/NCT01755689 |
Completed |
GlaxoSmithKline |
2014-04-29 |
| NCT01745679 |
Pharmacological Study of High Doses of Ceftriaxone in Meningitidis |
https://ClinicalTrials.gov/show/NCT01745679 |
Completed |
Nantes University Hospital |
2015-12-31 |
| NCT01732627 |
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older |
https://ClinicalTrials.gov/show/NCT01732627 |
Completed |
Sanofi |
2013-01-17 |
| NCT01725217 |
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia |
https://ClinicalTrials.gov/show/NCT01725217 |
Completed |
Novartis |
2013-03-31 |
| NCT01717638 |
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 |
https://ClinicalTrials.gov/show/NCT01717638 |
Completed |
Novartis |
2013-09-30 |
| NCT01682876 |
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. |
https://ClinicalTrials.gov/show/NCT01682876 |
Completed |
GlaxoSmithKline |
2013-07-02 |
| NCT01659996 |
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age |
https://ClinicalTrials.gov/show/NCT01659996 |
Completed |
Sanofi |
2014-11-30 |
| NCT01642589 |
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea |
https://ClinicalTrials.gov/show/NCT01642589 |
Completed |
Sanofi |
2013-01-31 |
| NCT01641042 |
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects |
https://ClinicalTrials.gov/show/NCT01641042 |
Completed |
GlaxoSmithKline |
2014-10-10 |
| NCT01593514 |
Understanding the Immune Response to Two Different Meningitis Vaccines |
https://ClinicalTrials.gov/show/NCT01593514 |
Completed |
University of Oxford |
2013-04-30 |
| NCT01589289 |
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC |
https://ClinicalTrials.gov/show/NCT01589289 |
Completed |
Institute of Tropical Medicine, Belgium |
2015-01-31 |
| NCT01580033 |
Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT01580033 |
Completed |
Jiangsu Province Centers for Disease Control and Prevention |
2012-09-30 |
| NCT01554124 |
Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis |
https://ClinicalTrials.gov/show/NCT01554124 |
Completed |
PENTA Foundation |
2014-12-31 |
| NCT01547715 |
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India |
https://ClinicalTrials.gov/show/NCT01547715 |
Completed |
Novartis |
2014-04-30 |
| NCT01543087 |
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose |
https://ClinicalTrials.gov/show/NCT01543087 |
Completed |
Pfizer |
2018-01-05 |
| NCT01540838 |
Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis |
https://ClinicalTrials.gov/show/NCT01540838 |
Completed |
University of Helsinki |
2017-02-28 |
| NCT01535469 |
Operational Research for Cryptococcal Antigen Screening |
https://ClinicalTrials.gov/show/NCT01535469 |
Completed |
University of Minnesota |
2015-06-30 |
| NCT01519713 |
Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects |
https://ClinicalTrials.gov/show/NCT01519713 |
Completed |
Sanofi |
2012-09-30 |
| NCT03927313 |
Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM |
https://ClinicalTrials.gov/show/NCT03927313 |
Recruiting |
University of Cape Town |
2020-06-30 |
| NCT01482052 |
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis |
https://ClinicalTrials.gov/show/NCT01482052 |
Completed |
JN-International Medical Corporation |
2013-01-31 |
| NCT01478347 |
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults |
https://ClinicalTrials.gov/show/NCT01478347 |
Completed |
Novartis |
2014-03-31 |
| NCT01466387 |
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults |
https://ClinicalTrials.gov/show/NCT01466387 |
Completed |
Novartis |
2012-04-30 |
| NCT01453348 |
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT01453348 |
Completed |
Novartis |
2012-01-31 |
| NCT01442675 |
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine |
https://ClinicalTrials.gov/show/NCT01442675 |
Completed |
Sanofi |
2012-06-30 |
| NCT01434680 |
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT01434680 |
Completed |
Novartis |
2012-11-30 |
| NCT01430611 |
Study of Sanofi Pasteur and Lanzhou Institute’s Meningococcal (Group A and C) Polysaccharide Vaccine in Children |
https://ClinicalTrials.gov/show/NCT01430611 |
Completed |
Sanofi |
2012-08-31 |
| NCT01428908 |
Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children |
https://ClinicalTrials.gov/show/NCT01428908 |
Completed |
Jiangsu Province Centers for Disease Control and Prevention |
2011-12-31 |
| NCT01424644 |
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents |
https://ClinicalTrials.gov/show/NCT01424644 |
Completed |
Novartis |
2012-12-31 |
| NCT01423084 |
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years |
https://ClinicalTrials.gov/show/NCT01423084 |
Completed |
Novartis |
2011-12-31 |
| NCT01410474 |
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan |
https://ClinicalTrials.gov/show/NCT01410474 |
Completed |
Novartis |
2012-01-31 |
| NCT01373710 |
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis |
https://ClinicalTrials.gov/show/NCT01373710 |
Completed |
Institut Curie |
2018-04-30 |
| NCT01367158 |
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines |
https://ClinicalTrials.gov/show/NCT01367158 |
Completed |
Novartis |
2012-01-31 |
| NCT01359449 |
Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations |
https://ClinicalTrials.gov/show/NCT01359449 |
Completed |
Sanofi |
2012-07-31 |
| NCT01345721 |
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT01345721 |
Completed |
Novartis |
2011-09-30 |
| NCT01340898 |
Immunogenicity and Safety Study of GSK Biologicals’ Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers |
https://ClinicalTrials.gov/show/NCT01340898 |
Completed |
GlaxoSmithKline |
2014-08-04 |
| NCT01339923 |
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years |
https://ClinicalTrials.gov/show/NCT01339923 |
Completed |
Novartis |
2014-01-31 |
| NCT04368429 |
Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age |
https://ClinicalTrials.gov/show/NCT04368429 |
Recruiting |
Sanofi |
2020-12-31 |
| NCT04358731 |
Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age |
https://ClinicalTrials.gov/show/NCT04358731 |
Recruiting |
Serum Institute of India Pvt. Ltd. |
2020-06-10 |
| NCT04236960 |
Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population. |
https://ClinicalTrials.gov/show/NCT04236960 |
Completed |
Walvax Biotechnology Co., Ltd. |
2019-09-16 |
| NCT04142242 |
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49 |
https://ClinicalTrials.gov/show/NCT04142242 |
Recruiting |
Sanofi |
2020-02-14 |
| NCT04135053 |
A Controlled Study to Assess Safety, Colonisation and Immunogenicity of Reconstituted Lyophilised Neisseria Lactamica |
https://ClinicalTrials.gov/show/NCT04135053 |
Recruiting |
University of Southampton |
2020-02-01 |
| NCT04084769 |
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4) |
https://ClinicalTrials.gov/show/NCT04084769 |
Active, not recruiting |
Sanofi |
2020-10-31 |
| NCT04080921 |
Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis |
https://ClinicalTrials.gov/show/NCT04080921 |
Completed |
Vinmec Research Institute of Stem Cell and Gene Technology |
2019-06-30 |
| NCT04031833 |
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) |
https://ClinicalTrials.gov/show/NCT04031833 |
Recruiting |
Matinas BioPharma Nanotechnologies, Inc. |
2021-04-30 |
| NCT03890367 |
Study of a Quadrivalent Meningococcal Conjugate Vaccine Compared With Two Meningococcal Reference Vaccines in Europeans Toddlers |
https://ClinicalTrials.gov/show/NCT03890367 |
Recruiting |
Sanofi |
2020-10-31 |
| NCT03787940 |
Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis |
https://ClinicalTrials.gov/show/NCT03787940 |
Recruiting |
Beijing Chest Hospital |
2021-12-31 |
| NCT03694405 |
Adolescent MenACWY Booster Study |
https://ClinicalTrials.gov/show/NCT03694405 |
Recruiting |
Canadian Immunization Research Network |
2020-12-31 |
| NCT03682939 |
Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population |
https://ClinicalTrials.gov/show/NCT03682939 |
Recruiting |
St George’s, University of London |
2020-06-30 |
| NCT03673462 |
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers |
https://ClinicalTrials.gov/show/NCT03673462 |
Recruiting |
Sanofi |
2023-03-31 |
| NCT03652610 |
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals’ Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age |
https://ClinicalTrials.gov/show/NCT03652610 |
Completed |
GlaxoSmithKline |
2019-01-17 |
| NCT03632720 |
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom |
https://ClinicalTrials.gov/show/NCT03632720 |
Recruiting |
Sanofi |
2022-06-30 |
| NCT03630705 |
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico |
https://ClinicalTrials.gov/show/NCT03630705 |
Recruiting |
Sanofi |
2022-12-31 |
| NCT03630250 |
Challenge of the Nasopharynx With Neisseria Lactamica Expressing the Meningococcal Protein Neisseria Adhesin A (NadA) |
https://ClinicalTrials.gov/show/NCT03630250 |
Completed |
University of Southampton |
2019-09-01 |
| NCT03587207 |
Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals’ MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years |
https://ClinicalTrials.gov/show/NCT03587207 |
Completed |
GlaxoSmithKline |
2018-12-19 |
| NCT03547271 |
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe |
https://ClinicalTrials.gov/show/NCT03547271 |
Recruiting |
Sanofi |
2023-08-31 |
| NCT03537508 |
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US |
https://ClinicalTrials.gov/show/NCT03537508 |
Recruiting |
Sanofi |
2022-12-31 |
| NCT03480191 |
Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis |
https://ClinicalTrials.gov/show/NCT03480191 |
Recruiting |
Centre Hospitalier Universitaire Dijon |
2021-06-30 |
| NCT03476135 |
Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children |
https://ClinicalTrials.gov/show/NCT03476135 |
Completed |
Sanofi |
2018-09-10 |
| NCT03421002 |
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis |
https://ClinicalTrials.gov/show/NCT03421002 |
Completed |
Astellas Pharma Inc |
2018-04-10 |
| NCT01266993 |
Persistence and Booster Study of GSK Biologicals’ Meningococcal Vaccine (GSK134612) in Healthy Children |
https://ClinicalTrials.gov/show/NCT01266993 |
Completed |
GlaxoSmithKline |
2014-03-31 |
| NCT01247909 |
Infant Severe Sepsis and Bacterial Meningitis in Malawi |
https://ClinicalTrials.gov/show/NCT01247909 |
Completed |
University of Malawi College of Medicine |
2015-02-28 |
| NCT01239043 |
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination |
https://ClinicalTrials.gov/show/NCT01239043 |
Completed |
Sanofi |
2011-04-30 |
| NCT01235975 |
Immunogenicity and Safety Study of GSK Biologicals’ Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years |
https://ClinicalTrials.gov/show/NCT01235975 |
Completed |
GlaxoSmithKline |
2011-07-29 |
| NCT01214837 |
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life |
https://ClinicalTrials.gov/show/NCT01214837 |
Completed |
Novartis |
2012-04-30 |
| NCT01210885 |
Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents |
https://ClinicalTrials.gov/show/NCT01210885 |
Completed |
Novartis |
2011-07-31 |
| NCT01192997 |
Comparison of Two Meningococcal ACWY Conjugate Vaccines |
https://ClinicalTrials.gov/show/NCT01192997 |
Completed |
Public Health England |
2013-10-31 |
| NCT01165242 |
Immunogenicity and Safety Study of GSK Biologicals’ Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults |
https://ClinicalTrials.gov/show/NCT01165242 |
Completed |
GlaxoSmithKline |
2011-02-25 |
| NCT01158755 |
Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study |
https://ClinicalTrials.gov/show/NCT01158755 |
Completed |
Universitas Padjadjaran |
2011-12-31 |
| NCT01154088 |
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevaxâ„¢ ACWY in Healthy 18-25 Year Olds |
https://ClinicalTrials.gov/show/NCT01154088 |
Completed |
GlaxoSmithKline |
2010-12-30 |
| NCT01148524 |
Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 |
https://ClinicalTrials.gov/show/NCT01148524 |
Completed |
Novartis |
2012-01-31 |
| NCT01148017 |
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT01148017 |
Completed |
Novartis |
2013-04-30 |
| NCT01144663 |
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines |
https://ClinicalTrials.gov/show/NCT01144663 |
Completed |
GlaxoSmithKline |
2012-06-22 |
| NCT01139021 |
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age |
https://ClinicalTrials.gov/show/NCT01139021 |
Completed |
Novartis |
2010-11-30 |
| NCT01129518 |
Can we Reduce the Number of Vaccine Injections for Children? |
https://ClinicalTrials.gov/show/NCT01129518 |
Completed |
University of Oxford |
2013-07-31 |
| NCT01086969 |
A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India |
https://ClinicalTrials.gov/show/NCT01086969 |
Completed |
Sanofi |
2011-02-28 |
| NCT01075152 |
Cryptococcal Optimal ART Timing Trial |
https://ClinicalTrials.gov/show/NCT01075152 |
Completed |
University of Minnesota |
2012-10-31 |
| NCT01049035 |
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers |
https://ClinicalTrials.gov/show/NCT01049035 |
Completed |
Sanofi |
2012-02-13 |
| NCT01027351 |
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine |
https://ClinicalTrials.gov/show/NCT01027351 |
Completed |
Novartis |
2010-09-30 |
| NCT01026974 |
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine |
https://ClinicalTrials.gov/show/NCT01026974 |
Completed |
Novartis |
2010-09-30 |
| NCT01018732 |
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY |
https://ClinicalTrials.gov/show/NCT01018732 |
Completed |
Novartis |
2010-07-31 |
| NCT01000311 |
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months |
https://ClinicalTrials.gov/show/NCT01000311 |
Completed |
Novartis |
2011-11-30 |
| NCT00976040 |
Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00976040 |
Completed |
Botswana-UPenn Partnership |
2011-11-30 |
| NCT00974363 |
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612 |
https://ClinicalTrials.gov/show/NCT00974363 |
Completed |
GlaxoSmithKline |
2013-05-31 |
| NCT00962624 |
Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults |
https://ClinicalTrials.gov/show/NCT00962624 |
Completed |
Public Health England |
2011-03-31 |
| NCT00955682 |
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612 |
https://ClinicalTrials.gov/show/NCT00955682 |
Completed |
GlaxoSmithKline |
2009-12-16 |
| NCT00944034 |
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 |
https://ClinicalTrials.gov/show/NCT00944034 |
Completed |
Novartis |
2011-08-31 |
| NCT00937521 |
Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants |
https://ClinicalTrials.gov/show/NCT00937521 |
Completed |
Novartis |
2010-11-30 |
| NCT00924820 |
A Pilot Study of Bevacizumab for Neoplastic Meningitis |
https://ClinicalTrials.gov/show/NCT00924820 |
Completed |
M.D. Anderson Cancer Center |
2015-09-30 |
| NCT00901940 |
Understanding the Immune Response to Meningitis Vaccines |
https://ClinicalTrials.gov/show/NCT00901940 |
Completed |
University of Oxford |
2010-10-31 |
| NCT00885703 |
High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals |
https://ClinicalTrials.gov/show/NCT00885703 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2017-01-12 |
| NCT00874549 |
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years |
https://ClinicalTrials.gov/show/NCT00874549 |
Completed |
Sanofi |
2008-01-31 |
| NCT00856297 |
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT00856297 |
Completed |
Novartis |
2012-11-30 |
| NCT00854867 |
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis. |
https://ClinicalTrials.gov/show/NCT00854867 |
Completed |
Mundipharma Research Limited |
2012-10-31 |
| NCT00850603 |
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® |
https://ClinicalTrials.gov/show/NCT00850603 |
Completed |
Sanofi |
2003-05-31 |
| NCT00847145 |
Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT00847145 |
Completed |
Novartis |
2010-08-31 |
| NCT00830856 |
Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa |
https://ClinicalTrials.gov/show/NCT00830856 |
Completed |
University of Zimbabwe |
2008-10-31 |
| NCT00806195 |
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants |
https://ClinicalTrials.gov/show/NCT00806195 |
Completed |
Novartis |
2011-03-31 |
| NCT03089086 |
South Australian Meningococcal B Vaccine Herd Immunity Study |
https://ClinicalTrials.gov/show/NCT03089086 |
Completed |
University of Adelaide |
2018-07-13 |
| NCT03433482 |
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals’ Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age |
https://ClinicalTrials.gov/show/NCT03433482 |
Completed |
GlaxoSmithKline |
2019-07-26 |
| NCT01962207 |
The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination |
https://ClinicalTrials.gov/show/NCT01962207 |
Completed |
Pfizer |
2017-12-31 |
| NCT03691610 |
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers |
https://ClinicalTrials.gov/show/NCT03691610 |
Recruiting |
Sanofi |
2024-05-31 |
| NCT00777790 |
Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents |
https://ClinicalTrials.gov/show/NCT00777790 |
Completed |
Sanofi |
2004-04-30 |
| NCT00777257 |
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine |
https://ClinicalTrials.gov/show/NCT00777257 |
Completed |
Sanofi |
2007-03-31 |
| NCT00774384 |
Regulation of Mucosal Immune Response to Systemic MenB Vaccine |
https://ClinicalTrials.gov/show/NCT00774384 |
Completed |
University Hospitals Bristol NHS Foundation Trust |
2011-11-30 |
| NCT00772070 |
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT00772070 |
Completed |
Sanofi |
2003-08-31 |
| NCT00771849 |
Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children |
https://ClinicalTrials.gov/show/NCT00771849 |
Completed |
Sanofi |
2004-03-31 |
| NCT00758264 |
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration |
https://ClinicalTrials.gov/show/NCT00758264 |
Completed |
GlaxoSmithKline |
2009-06-02 |
| NCT00721396 |
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules |
https://ClinicalTrials.gov/show/NCT00721396 |
Completed |
Novartis |
2010-07-31 |
| NCT00718666 |
The Long-term Antibody Persistence of GSK Biologicals’ Meningococcal Vaccine GSK134612 in Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT00718666 |
Completed |
GlaxoSmithKline |
2013-11-13 |
| NCT00715910 |
The Long-term Antibody Persistence of GSK Biologicals’ Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults |
https://ClinicalTrials.gov/show/NCT00715910 |
Completed |
GlaxoSmithKline |
2013-04-30 |
| NCT00715234 |
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients |
https://ClinicalTrials.gov/show/NCT00715234 |
Completed |
University of Colorado, Denver |
2009-12-31 |
| NCT00707785 |
Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis |
https://ClinicalTrials.gov/show/NCT00707785 |
Completed |
Johns Hopkins University |
2011-04-30 |
| NCT00700713 |
Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26 |
https://ClinicalTrials.gov/show/NCT00700713 |
Completed |
Sanofi |
2009-02-28 |
| NCT00700635 |
Dose Comparison Study of Menactra® in US Children |
https://ClinicalTrials.gov/show/NCT00700635 |
Completed |
Sanofi |
2009-05-31 |
| NCT00678652 |
Phase 1 Safety and Immunogenicity of Meningococcal Vaccine |
https://ClinicalTrials.gov/show/NCT00678652 |
Completed |
U.S. Army Medical Research and Development Command |
2009-08-31 |
| NCT00674674 |
Phase 1 Intrathecal Topotecan for Neoplastic Meningitis |
https://ClinicalTrials.gov/show/NCT00674674 |
Completed |
Baylor College of Medicine |
2010-08-31 |
| NCT00674583 |
Comparison of GSK Biologicals’ Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children |
https://ClinicalTrials.gov/show/NCT00674583 |
Completed |
GlaxoSmithKline |
2008-09-02 |
| NCT00667602 |
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers |
https://ClinicalTrials.gov/show/NCT00667602 |
Completed |
Novartis |
2009-07-31 |
| NCT00661713 |
Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules |
https://ClinicalTrials.gov/show/NCT00661713 |
Completed |
Novartis |
2010-04-30 |
| NCT00661557 |
Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects |
https://ClinicalTrials.gov/show/NCT00661557 |
Completed |
GlaxoSmithKline |
2008-12-19 |
| NCT00643916 |
Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age |
https://ClinicalTrials.gov/show/NCT00643916 |
Completed |
Sanofi |
2006-03-31 |
| NCT00631995 |
Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers |
https://ClinicalTrials.gov/show/NCT00631995 |
Completed |
Sanofi |
2009-02-28 |
| NCT00626327 |
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT00626327 |
Completed |
Novartis |
2010-07-31 |
| NCT00625677 |
Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life |
https://ClinicalTrials.gov/show/NCT00625677 |
Completed |
Public Health England |
2010-03-31 |
| NCT00619203 |
Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis |
https://ClinicalTrials.gov/show/NCT00619203 |
Completed |
University of Malawi College of Medicine |
2012-03-31 |
| NCT00616421 |
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children |
https://ClinicalTrials.gov/show/NCT00616421 |
Completed |
Novartis |
2009-04-30 |
| NCT00614614 |
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 |
https://ClinicalTrials.gov/show/NCT00614614 |
Completed |
GlaxoSmithKline |
2009-07-31 |
| NCT00601731 |
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months |
https://ClinicalTrials.gov/show/NCT00601731 |
Completed |
Novartis |
2010-07-31 |
| NCT00560313 |
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults |
https://ClinicalTrials.gov/show/NCT00560313 |
Completed |
Novartis |
2009-11-30 |
| NCT00539032 |
Immunology and Safety of Menactra® in Children in Saudi Arabia |
https://ClinicalTrials.gov/show/NCT00539032 |
Completed |
Sanofi |
2008-08-31 |
| NCT00518180 |
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents |
https://ClinicalTrials.gov/show/NCT00518180 |
Completed |
Novartis |
2008-04-30 |
| NCT00514904 |
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevaxâ„¢ in 2-10 Year Old Subjects |
https://ClinicalTrials.gov/show/NCT00514904 |
Completed |
GlaxoSmithKline |
2008-09-03 |
| NCT00508261 |
Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexaâ„¢ Versus Individual Administration of Each Vaccine |
https://ClinicalTrials.gov/show/NCT00508261 |
Completed |
GlaxoSmithKline |
2008-05-26 |
| NCT00488683 |
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants |
https://ClinicalTrials.gov/show/NCT00488683 |
Completed |
Novartis |
2009-05-31 |
| NCT00483574 |
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT00483574 |
Completed |
Sanofi |
2009-01-31 |
| NCT00474526 |
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants |
https://ClinicalTrials.gov/show/NCT00474526 |
Completed |
Novartis |
2008-09-30 |
| NCT00474487 |
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults |
https://ClinicalTrials.gov/show/NCT00474487 |
Completed |
Novartis |
2007-08-31 |
| NCT00474266 |
Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetraâ„¢ to 12-23 Month-Old Children |
https://ClinicalTrials.gov/show/NCT00474266 |
Completed |
GlaxoSmithKline |
2008-02-26 |
| NCT00471081 |
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers. |
https://ClinicalTrials.gov/show/NCT00471081 |
Completed |
GlaxoSmithKline |
2008-10-23 |
| NCT00465816 |
Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals’ Meningococcal Vaccine 134612 |
https://ClinicalTrials.gov/show/NCT00465816 |
Completed |
GlaxoSmithKline |
2008-04-28 |
| NCT00464815 |
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevaxâ„¢ in 11-17 Year-Old Subjects |
https://ClinicalTrials.gov/show/NCT00464815 |
Completed |
GlaxoSmithKline |
2008-04-16 |
| NCT00459316 |
Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth |
https://ClinicalTrials.gov/show/NCT00459316 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2013-03-31 |
| NCT00454909 |
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years. |
https://ClinicalTrials.gov/show/NCT00454909 |
Completed |
GlaxoSmithKline |
2007-10-31 |
| NCT00453986 |
Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarixâ„¢ to 18-55 Year-Old Adults |
https://ClinicalTrials.gov/show/NCT00453986 |
Completed |
GlaxoSmithKline |
2007-11-30 |
| NCT00450437 |
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults |
https://ClinicalTrials.gov/show/NCT00450437 |
Completed |
Novartis |
2007-08-31 |
| NCT00444951 |
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia |
https://ClinicalTrials.gov/show/NCT00444951 |
Completed |
Sanofi |
2008-02-29 |
| NCT00433914 |
Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants |
https://ClinicalTrials.gov/show/NCT00433914 |
Completed |
Novartis |
2007-12-31 |
| NCT00427908 |
Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612 |
https://ClinicalTrials.gov/show/NCT00427908 |
Completed |
GlaxoSmithKline |
2007-12-03 |
| NCT00427076 |
Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections |
https://ClinicalTrials.gov/show/NCT00427076 |
Completed |
Rabin Medical Center |
2014-05-31 |
| NCT00422292 |
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT00422292 |
Completed |
Sanofi |
2009-01-31 |
| NCT00392808 |
Immunogenicity of the Booster Dose of Two MenC Vaccines |
https://ClinicalTrials.gov/show/NCT00392808 |
Completed |
Centro Superior de Investigación en Salud Publica |
2008-05-31 |
| NCT00390143 |
Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612 |
https://ClinicalTrials.gov/show/NCT00390143 |
Completed |
GlaxoSmithKline |
2009-05-31 |
| NCT00384397 |
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT00384397 |
Completed |
Sanofi |
2008-08-31 |
| NCT00356369 |
Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT00356369 |
Completed |
GlaxoSmithKline |
2007-09-07 |
| NCT00355121 |
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® |
https://ClinicalTrials.gov/show/NCT00355121 |
Completed |
Sanofi |
2009-06-30 |
| NCT00329901 |
Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years |
https://ClinicalTrials.gov/show/NCT00329901 |
Completed |
Novartis |
2007-05-31 |
| NCT00329849 |
Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age |
https://ClinicalTrials.gov/show/NCT00329849 |
Completed |
Novartis |
2007-03-31 |
| NCT00317109 |
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevaxâ„¢ ACW at 24 to 30 m in Primed Subjects |
https://ClinicalTrials.gov/show/NCT00317109 |
Completed |
GlaxoSmithKline |
2007-05-01 |
| NCT00316654 |
Persistence of Antibody Response to N. Meningitidis Group C in Children |
https://ClinicalTrials.gov/show/NCT00316654 |
Completed |
Novartis |
2005-10-31 |
| NCT00311415 |
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children |
https://ClinicalTrials.gov/show/NCT00311415 |
Completed |
Novartis |
2008-04-30 |
| NCT00310856 |
Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months) |
https://ClinicalTrials.gov/show/NCT00310856 |
Completed |
Novartis |
2006-11-30 |
| NCT00310817 |
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. |
https://ClinicalTrials.gov/show/NCT00310817 |
Completed |
Novartis |
2006-05-31 |
| NCT00310713 |
Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine |
https://ClinicalTrials.gov/show/NCT00310713 |
Completed |
Novartis |
2006-08-31 |
| NCT00310700 |
Kinetics of B Cell Response in Infants Menjugate Vaccination |
https://ClinicalTrials.gov/show/NCT00310700 |
Completed |
Novartis |
2005-11-30 |
| NCT00310687 |
Persistence of Immune Response After Vaccination With MCC |
https://ClinicalTrials.gov/show/NCT00310687 |
Completed |
Novartis |
2005-12-31 |
| NCT00310674 |
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age |
https://ClinicalTrials.gov/show/NCT00310674 |
Completed |
Novartis |
NA |
| NCT00310635 |
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age |
https://ClinicalTrials.gov/show/NCT00310635 |
Completed |
Novartis |
NA |
| NCT00297817 |
Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents |
https://ClinicalTrials.gov/show/NCT00297817 |
Completed |
Novartis |
2007-04-30 |
| NCT00291343 |
Immune Response & Safety of GSK Biologicals’ Mencevaxâ„¢ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study |
https://ClinicalTrials.gov/show/NCT00291343 |
Completed |
GlaxoSmithKline |
2007-03-15 |
| NCT00290329 |
Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years |
https://ClinicalTrials.gov/show/NCT00290329 |
Completed |
GlaxoSmithKline |
2006-10-01 |
| NCT00271479 |
Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine |
https://ClinicalTrials.gov/show/NCT00271479 |
Completed |
Epicentre |
NA |
| NCT00269477 |
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® |
https://ClinicalTrials.gov/show/NCT00269477 |
Completed |
Sanofi |
2007-02-28 |
| NCT00262041 |
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents |
https://ClinicalTrials.gov/show/NCT00262041 |
Completed |
Novartis |
2006-03-31 |
| NCT00262028 |
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children |
https://ClinicalTrials.gov/show/NCT00262028 |
Completed |
Novartis |
2006-11-30 |
| NCT00262002 |
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants |
https://ClinicalTrials.gov/show/NCT00262002 |
Completed |
Novartis |
2005-07-31 |
| NCT00258856 |
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® |
https://ClinicalTrials.gov/show/NCT00258856 |
Completed |
Sanofi |
2007-03-31 |
| NCT00248833 |
Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis. |
https://ClinicalTrials.gov/show/NCT00248833 |
Completed |
U.S. Army Medical Research and Development Command |
2006-11-30 |
| NCT00227422 |
Assess the Non-inferiority of GSK Biologicals’ Mencevaxâ„¢ ACWY (Manufactured by a New Process) vs Mencevaxâ„¢ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs |
https://ClinicalTrials.gov/show/NCT00227422 |
Completed |
GlaxoSmithKline |
NA |
| NCT00197808 |
Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines |
https://ClinicalTrials.gov/show/NCT00197808 |
Completed |
Public Health England |
2010-01-31 |
| NCT00196976 |
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old |
https://ClinicalTrials.gov/show/NCT00196976 |
Completed |
GlaxoSmithKline |
2006-03-01 |
| NCT00196963 |
Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs |
https://ClinicalTrials.gov/show/NCT00196963 |
Completed |
GlaxoSmithKline |
2005-07-31 |
| NCT00196950 |
Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years |
https://ClinicalTrials.gov/show/NCT00196950 |
Completed |
GlaxoSmithKline |
2003-10-31 |
| NCT00161928 |
Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants |
https://ClinicalTrials.gov/show/NCT00161928 |
Completed |
Pfizer |
NA |
| NCT00145249 |
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis |
https://ClinicalTrials.gov/show/NCT00145249 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2008-04-30 |
| NCT00137917 |
Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs |
https://ClinicalTrials.gov/show/NCT00137917 |
Completed |
GlaxoSmithKline |
2003-06-30 |
| NCT00135564 |
Study to Evaluate GlaxoSmithKline (GSK) Biologicals’ MenC-TT and Hib-MenC-TT or Meningitecâ„¢ in Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT00135564 |
Completed |
GlaxoSmithKline |
2003-07-31 |
| NCT00135486 |
Study to Evaluate GlaxoSmithKline (GSK) Biologicals’ MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants |
https://ClinicalTrials.gov/show/NCT00135486 |
Completed |
GlaxoSmithKline |
2003-01-31 |
| NCT00126984 |
Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT00126984 |
Completed |
GlaxoSmithKline |
2008-02-29 |
| NCT00126945 |
Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs |
https://ClinicalTrials.gov/show/NCT00126945 |
Completed |
GlaxoSmithKline |
NA |
| NCT00029523 |
DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor |
https://ClinicalTrials.gov/show/NCT00029523 |
Completed |
Pacira Pharmaceuticals, Inc |
NA |
| NCT00012467 |
Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00012467 |
Completed |
InterMune |
NA |
| NCT00002316 |
The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00002316 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002306 |
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B |
https://ClinicalTrials.gov/show/NCT00002306 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002305 |
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00002305 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002294 |
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS |
https://ClinicalTrials.gov/show/NCT00002294 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002113 |
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. |
https://ClinicalTrials.gov/show/NCT00002113 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002077 |
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00002077 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002076 |
Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00002076 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002075 |
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00002075 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002074 |
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome |
https://ClinicalTrials.gov/show/NCT00002074 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002068 |
A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00002068 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002040 |
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00002040 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002019 |
Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome |
https://ClinicalTrials.gov/show/NCT00002019 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002010 |
Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis |
https://ClinicalTrials.gov/show/NCT00002010 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00001017 |
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS |
https://ClinicalTrials.gov/show/NCT00001017 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
1991-07-31 |
| NCT00000776 |
Dexamethasone in Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00000776 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00000708 |
Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00000708 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
1991-07-31 |
| NCT00000677 |
SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy |
https://ClinicalTrials.gov/show/NCT00000677 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00000639 |
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis |
https://ClinicalTrials.gov/show/NCT00000639 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |